Physician profile
Eric T Lee
NPI 1982790812
$21,236.68
in general payments reported to CMS, 2019-2025
50 companies · $2,412 in 2025
The $2,412 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,530 · 2020: $2,675 · 2021: $2,676 · 2022: $2,659 · 2023: $2,921 · 2024: $4,362 · 2025: $2,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,188 · Travel and Lodging: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,187.59 |
| Travel and Lodging | $1,508.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $2,080.98 | 2023-2025 | Prospera, Biotronik |
| Novartis Pharmaceuticals Corporation | $1,945.44 | 2019-2025 | |
| Boston Scientific Corporation | $1,743.67 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Accolade Sr, Ingevity+ |
| Amgen INC. | $1,415.66 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $1,312.89 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Pfizer INC. | $1,281.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,088.47 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $1,009.46 | 2020-2023 | Aveir, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $959.96 | 2019-2025 | Jardiance |
| Medtronic Vascular, INC. | $842.72 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $811.63 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $743.67 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $692.40 | 2019-2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $650.37 | 2019-2024 | Xarelto |
| Medtronic, INC. | $438.57 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Linq II |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.